Highlights: Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Quis ipsum suspendisse ultrices gravida. Read more

Unlock the Potential of Advanced Nanotechnologies

What We Do

At LamdaGen, we are committed to reshaping the field of advanced nanotechnologies by delivering innovative solutions tailored to meet the critical demands of various industries. Our pioneering technologies enable the creation of simple, advanced, and cost-effective systems that redefine speed and precision. Our robust and adaptable nanotechnologies support a wide range of applications, including human health, environmental monitoring, industrial processes, and bioresearch.

For bio-applications, the LAuRA™ platform, powered by LamdaGen’s Plasmonic Amplification Technology™ (PAT™), presents an exemplary alternative for collaborators and companies seeking to enhance their diagnostic/detection capabilities. We employ our well-established plasmonic biosensing surfaces to enhance the sensitivity and precision of diagnostic tools and biosensors. These innovations are ideal for early disease detection, personalized medicine, and advanced biotarget detection, ensuring reliable and rapid results in complex biological environments.

In addition to our primary focus areas, we are developing advanced solutions aimed at enhancing the efficiency and performance of nano-based catalytic processes. Our proprietary surface technologies are meticulously engineered to optimize reactions and significantly improve the overall effectiveness of catalysis. These innovations have broad applications, including energy conversion technologies, biothreat mitigation, and environmental remediation, offering transformative potential across multiple sectors.

We pride ourselves on fostering close collaborations with our partners and clients, ensuring the seamless integration of our technologies into their research, development, services, and products. By adhering to the principles of technological excellence and practical application, LamdaGen leverages a licensing model that extends its nano-based technologies across diverse sectors.

LAuRA™ Plasmonic Sensing, powered by PAT™

Fast Results

High Sensitivity

Patented Technology

Easy to Integrate

Easy to Use

LAuRA Rapid Test System

LAuRA (LamdaGen Au (gold) Rapid Assay) offers a turnkey plasmonic biosensing solution, combining the speed and convenience of lateral flow assays with the high sensitivity and quantitation of ELISA tests.

The LAuRA Rapid Test System delivers laboratory quality results equivalent to gold standard ELISA’s in minutes rather than hours. LAuRA’s test procedure is simple and easy to use. Disposable cartridges can be designed to run single or multi-target tests and deliver results 15 minutes or less.

Leveraging the inherent properties of advanced nano-based plasmonics, the LAuRA immuno-based platform provides high sensitivity detection capabilities far exceeding those of existing rapid assays. The patented platform is flexible and scalable, enabling uniquely powerful detection systems ranging from small benchtops to handhelds to throughput. 

Innovative LAuRA systems are being developed for applications in Human Health, Food & Water Safety, and Animal Health.

What would you like to learn?

Technology

LAuRA, powered by PAT harnesses the unique properties of plasmonics to revolutionize diagnostic detection

Applications

See how LAuRA delivers results with speed, sensitivity and convenience like no other platform

About Us

LamdaGen is taking a One Health approach to improve the performance and accessibility of rapid testing

Latest News

LamdaGen Corporation Partners with MRIGlobal and JPEO-CBRND for Bacteriophage-Based Protein Detection of a Priority Biothreat
LamdaGen Corporation Partners with MRIGlobal and JPEO-CBRND for Bacteriophage-Based Protein Detection of a Priority BiothreatOctober 23, 2023
Read More
LamdaGen Corporation, a developer of nano-based plasmonic biosensor technology has entered into a subcontract with MRIGlobal and JPEO-CBRND to undertake proof-of-concept studies for the detection of a priority biothreat using immobilized phage receptor-binding proteins...
LamdaGen Corporation Forms Strategic Advisory Board - Appoints Diagnostic Industry Leaders as Inaugural Members
LamdaGen Corporation Forms Strategic Advisory Board - Appoints Diagnostic Industry Leaders as Inaugural Members June 22, 2023
Read More
LamdaGen Corporation, an emerging diagnostic technology company with a powerful, plasmonic platform for rapid diagnostic/detection testing, is pleased to announce the members of its newly-formed Strategic Advisory Board (SAB). The inaugural SAB members represent a distinguished set of experts who bring a depth and breadth of leadership, innovation and product commercialization experience in the life science, diagnostic, pharmaceutical and food safety industries.
LamdaGen’s LSPR-based Plasmonic Biosensors vs. Gold Colloids and other optical technologies: The Sensing Range & Quality Factor
LamdaGen’s LSPR-based Plasmonic Biosensors vs. Gold Colloids and other optical technologies: The Sensing Range & Quality FactorMarch 24, 2022
Read More
This brief describes the optical properties of LamdaGen’s gold plasmonic sensor surfaces compared to the optical properties of gold (Au) colloids. As we will show, the plasmonic films are superior to gold colloidal solutions for biosensing. In fact, the optical properties of the plasmonic films match those of single Au nano-rods, one of the most sensitive techniques for biosensing as interrogated a single particle at a time. While biosensing at the single molecule level poses enormous challenges commercially, the patented manufacturing process of LamdaGen’s continuous nano-structured thin-films is highly reproducible, scalable and economic. Thus, the plasmonic films bring the benefits of the nanoscopic world into the commercial realm.
LamdaGen Corporation receives Grant Notification from Indian Patent Office for Patent Number 360405, ENZYMATIC ASSAY FOR LSPR
LamdaGen Corporation receives Grant Notification from Indian Patent Office for Patent Number 360405, ENZYMATIC ASSAY FOR LSPRMarch 11, 2021
Read More
LamdaGen Corporation, a privately-owned company focused on the development and commercialization of plasmonic biosensor systems for Point of Care (POC) diagnostics, announced today the Indian Patent Office has granted and recorded patent 360405 titled ENZYMATIC ASSAY FOR LSPR which enables
LamdaGen Corporation receives Official Notice from the USPTO of Allowance of Patent: DIGITAL LSPR FOR ENHANCED ASSAY SENSITIVITY
LamdaGen Corporation receives Official Notice from the USPTO of Allowance of Patent: DIGITAL LSPR FOR ENHANCED ASSAY SENSITIVITYJanuary 18, 2021
Read More
MENLO PARK, CA, January 18, 2021— LamdaGen Corporation, a privately-owned company focused on the development and commercialization of plasmonic biosensor systems for Point of Care (POC) diagnostics, announced today the United States Patent and Trademark Office has given Official Notice
LamdaGen Corporation receives Official Notice of Allowance from the Japanese Patent Office for issuance of patent: MOBILE/WEARABLE DEVICES INCORPORATING LSPR SENSORS
LamdaGen Corporation receives Official Notice of Allowance from the Japanese Patent Office for issuance of patent: MOBILE/WEARABLE DEVICES INCORPORATING LSPR SENSORSJanuary 8, 2021
Read More
MENLO PARK, CA, January 8, 2021— LamdaGen Corporation, a developer of plasmonic biosensor systems for diagnostics, announced the Japanese Patent Office has given Official Notice of Allowance to its patent application entitled MOBILE/WEARABLE DEVICES INCORPORATING LSPR SENSORS which enables high
A Breakdown of the Reported Sensitivities of SARS-CoV-2 Diagnostic Assays and Implications for the Sensitivity Required for Rapid Antigen Tests
A Breakdown of the Reported Sensitivities of SARS-CoV-2 Diagnostic Assays and Implications for the Sensitivity Required for Rapid Antigen TestsOctober 14, 2020
Read More
The viral load of SARS-CoV-2 in patients charted as determined in hospital settings across several regions of the world.[1-4] In three studies, the pool includes a limited number patients with mild to moderate symptoms in hospitals,
Previous
Next

Interested in our biosensors & collaborative opportunities?

Contact us to explore how our detection technologies can benefit your R&D, Services and Product objectives.

Let’s discuss possibilities and drive innovation together.